EligibleTrials

Mitigating the Pro-inflammatory Phenotype of Obesity

Recruiting · NCT04934228 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Kansas Medical Center

View the official record on ClinicalTrials.gov →
Obesity

Interventions studied

Clonidine PillHydrochlorothiazide 12.5Mg TabPlacebo

What this trial is about

The purpose of this study is to examine the hypothesize that 4 weeks of sympathetic nerve activity (SNA) inhibition (oral clonidine) will cause a significant reduction in circulating blood concentrations and endothelial cell expression of inflammatory markers (e.g., TNF-α, IL-6). Our study is a prospective study using a randomized, double-blinded design to test 4 weeks of SNA blockade (oral clonidine) compared with a BP-lowering control condition (diuretic, hydrochlorothiazide) or a placebo.

Who can take part

Age range
18 Years to 79 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed across 1 US state.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.